A paper published Sunday in the New England Journal of Medicine. For the small study, all 18 patients were given dostarlimab, a checkpoint inhibitor. The results were astounding. Every patient’s cancer disappeared, undetectable by physical examination, endoscopy, PET scans, or M.R.I. scans.
Dr. Hanna K. Sanoff, MD, MPH, an associate professor of medicine in the Division of Oncology in the Department of Medicine at the University of North Carolina, wrote an editorial accompanying the paper. Dr. Sanoff, who was not involved in the study, called it “small but compelling.” She added, though, that it is not clear if the patients are cured.
“Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure,” Dr. Sanoff said in the editorial.
[Read more via The New York Times]